Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;9(4):1528-1536.
doi: 10.3892/etm.2015.2277. Epub 2015 Feb 9.

Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis

Liqiong Hou  1 , Tieyun Zhao  1 , Yunhui Liu  1 , Yiyi Zhang  1
Affiliations

Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis

Liqiong Hou et al. Exp Ther Med. 2015 Apr.

Abstract

Previous randomized controlled trials (RCTs) have reported conflicting results for the efficacy of sitagliptin and sulfonylurea therapy in patients with type 2 diabetes mellitus showing inadequate glycemic control with metformin monotherapy. To clarify these findings, a meta-analysis was conducted of the outcomes of all published RCTs comparing sitagliptin with sulfonylureas in the treatment of type 2 diabetes mellitus. Standard medical databases were searched to identify relevant English- and Chinese-language RCTs. RCT results were compared regarding the mean change in glycated hemoglobin (HbA1c) level; the proportion achieving <7% HbAlc; and a change in body weight. No significant differences were found between the metformin plus sitagliptin and metformin plus sulfonylurea groups regarding HbAlc or the proportion achieving <7% HbAlc, while the metformin plus sitagliptin group experienced fewer hypoglycemic events (P<0.00001) and a greater reduction in body weight (P<0.00001). Metformin plus sitagliptin therapy may decrease HbAlc values in patients with type 2 diabetes mellitus who are not achieving their glycemic targets with metformin monotherapy in a manner similar to metformin plus sulfonylurea therapy, whilst posing a lower risk of hypoglycemia, and yielding a more beneficial effect on body weight.

Keywords: diabetes mellitus; metformin; sitagliptin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of search results.
Figure 2
Figure 2
Comparison of changes in glycated hemoglobin between the metformin plus sitagliptin and the metformin plus sulfonylurea groups. SD, standard deviation; CI, confidence interval; df, degrees of freedom.
Figure 3
Figure 3
Comparison of achievements of <7% glycated hemoglobin between the metformin plus sitagliptin and the metformin plus sulfonylurea groups. M-H, Mantel-Haenszel; CI, confidence interval.
Figure 4
Figure 4
Comparison of changes in body weight between the metformin plus sitagliptin and the metformin plus sulfonylurea groups. SD, standard deviation; CI, confidence interval.
Figure 5
Figure 5
Comparison of occurrence of hypoglycemic events between the metformin plus sitagliptin and the metformin plus sulfonylurea groups. M-H, Mantel-Haenszel; CI, confidence interval.
See this image and copyright information in PMC

References

    1. Stulc T, Sedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract. 2010;88:125–131. doi: 10.1016/j.diabres.2010.02.017. - DOI - PubMed
    1. Choudhury SR, Datta A, Chanda S, et al. Overview of current and upcoming strategies implied for the therapy of type 2 diabetes mellitus. Curr Diabetes Rev. 2014;10:275–282. doi: 10.2174/1573399810666140825154815. - DOI - PubMed
    1. Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ. 2007;335:497. doi: 10.1136/bmj.39314.620174.80. - DOI - PMC - PubMed
    1. Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;3:CD002966. - PubMed
    1. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med. 2006;23:579–593. doi: 10.1111/j.1464-5491.2006.01918.x. - DOI - PubMed

LinkOut - more resources